Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.06 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | hard to drug | 0.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | in no curated pathway | 0.00 |
No case: the score is under the bar. Receipt 4240
Sealed predictions
- NXNL2 in dopamine neurons, braak-0.07 (p 0.849) → -0.10 (p 0.805)receipt 4247
Swarm cases
receipt 4247: NXNL2 in dopamine neurons, braak
- power
- full sample -0.09 (p 0.722, n 18), 95% CI -0.53 to +0.39. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.09 (p 0.715, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.24 (p 0.346, n 18). could be the mix.
- skeptic
- leave-one-out range -0.22 to +0.02, sign flips 2; without severely affected donors -0.09 (p 0.722, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for NXNL2 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts